These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 21410453)

  • 1. The calcium-sensing receptor and calcimimetics in blood pressure modulation.
    Smajilovic S; Yano S; Jabbari R; Tfelt-Hansen J
    Br J Pharmacol; 2011 Oct; 164(3):884-93. PubMed ID: 21410453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of calcimimetics in children with normal kidney function.
    VanSickle JS; Srivastava T; Alon US
    Pediatr Nephrol; 2019 Mar; 34(3):413-422. PubMed ID: 29552709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allosteric modulators of the extracellular calcium receptor.
    Nemeth EF
    Drug Discov Today Technol; 2013; 10(2):e277-84. PubMed ID: 24050279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease.
    Torres PA; De Broe M
    Kidney Int; 2012 Jul; 82(1):19-25. PubMed ID: 22437409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcimimetic and Calcilytic Drugs: Feats, Flops, and Futures.
    Nemeth EF; Goodman WG
    Calcif Tissue Int; 2016 Apr; 98(4):341-58. PubMed ID: 26319799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular actions of calcimimetics: role of Ca²(+) -sensing receptors versus Ca²(+) influx through L-type Ca²(+) channels.
    Thakore P; Ho WS
    Br J Pharmacol; 2011 Feb; 162(3):749-62. PubMed ID: 20958288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and Development of Calcimimetic and Calcilytic Compounds.
    Nemeth EF; Van Wagenen BC; Balandrin MF
    Prog Med Chem; 2018; 57(1):1-86. PubMed ID: 29680147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional proteins involved in regulation of intracellular Ca(2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics.
    Nagano N; Nemeth EF
    J Pharmacol Sci; 2005 Mar; 97(3):355-60. PubMed ID: 15781990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium sensing receptor activators: calcimimetics.
    Harrington PE; Fotsch C
    Curr Med Chem; 2007; 14(28):3027-34. PubMed ID: 18220738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biased allosteric modulation at the CaS receptor engendered by structurally diverse calcimimetics.
    Cook AE; Mistry SN; Gregory KJ; Furness SG; Sexton PM; Scammells PJ; Conigrave AD; Christopoulos A; Leach K
    Br J Pharmacol; 2015 Jan; 172(1):185-200. PubMed ID: 25220431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of calcium-sensing receptor in mineral ion metabolism and inherited disorders of calcium-sensing.
    Chattopadhyay N; Brown EM
    Mol Genet Metab; 2006 Nov; 89(3):189-202. PubMed ID: 16919492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allosteric modulation of the calcium-sensing receptor.
    Jensen AA; Bräuner-Osborne H
    Curr Neuropharmacol; 2007 Sep; 5(3):180-6. PubMed ID: 19305800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism.
    Kawata T; Imanishi Y; Kobayashi K; Kenko T; Wada M; Ishimura E; Miki T; Nagano N; Inaba M; Arnold A; Nishizawa Y
    Eur J Endocrinol; 2005 Oct; 153(4):587-94. PubMed ID: 16189180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasculotropic effects of calcimimetics.
    Koleganova N; Piecha G; Ritz E
    Curr Opin Nephrol Hypertens; 2010 Jan; 19(1):32-6. PubMed ID: 19816173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders.
    Nemeth EF; Shoback D
    Best Pract Res Clin Endocrinol Metab; 2013 Jun; 27(3):373-84. PubMed ID: 23856266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism.
    Nagano N
    Pharmacol Ther; 2006 Mar; 109(3):339-65. PubMed ID: 16102839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drugs inhibiting parathyroid hormone (PTH) secretion by control of the calcium receptor (calcimimetics)--effect on the set point of calcium-regulated PTH secretion].
    Nagano N
    Clin Calcium; 2005 Jan; 15(1):71-8. PubMed ID: 15632475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcimimetics increase CaSR expression and reduce mineralization in vascular smooth muscle cells: mechanisms of action.
    Hénaut L; Boudot C; Massy ZA; Lopez-Fernandez I; Dupont S; Mary A; Drüeke TB; Kamel S; Brazier M; Mentaverri R
    Cardiovasc Res; 2014 Feb; 101(2):256-65. PubMed ID: 24217682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Calcimimetics].
    Messa P; Como G; Brezzi B
    G Ital Nefrol; 2006; 23(1):12-21. PubMed ID: 16521071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Calcimimetics--a new treatment for hyperparathyroidism?].
    Piecha G; Chudek J; Wiecek A
    Pol Merkur Lekarski; 2005 May; 18(107):581-4. PubMed ID: 16161961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.